Reviewing Achieve Life Sciences Inc. (ACHV)’s and Vaxart Inc. (NASDAQ:VXRT)’s results

Achieve Life Sciences Inc. (NASDAQ:ACHV) and Vaxart Inc. (NASDAQ:VXRT), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Achieve Life Sciences Inc. N/A 0.00 12.79M -8.12 0.00
Vaxart Inc. 4.16M 2.66 18.35M -2.47 0.00

Table 1 demonstrates Achieve Life Sciences Inc. and Vaxart Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Achieve Life Sciences Inc. 0.00% -114.6% -93.5%
Vaxart Inc. -441.11% -91% -40.7%

Risk & Volatility

Achieve Life Sciences Inc. has a beta of 2.78 and its 178.00% more volatile than Standard and Poor’s 500. Competitively, Vaxart Inc. is 42.00% less volatile than Standard and Poor’s 500, because of the 0.58 beta.

Liquidity

4.6 and 4.6 are the respective Current Ratio and a Quick Ratio of Achieve Life Sciences Inc. Its rival Vaxart Inc.’s Current and Quick Ratios are 2 and 2 respectively. Achieve Life Sciences Inc. has a better chance of clearing its pay short and long-term debts than Vaxart Inc.

Institutional and Insider Ownership

Institutional investors held 26.7% of Achieve Life Sciences Inc. shares and 52.2% of Vaxart Inc. shares. Achieve Life Sciences Inc.’s share held by insiders are 4.97%. Competitively, Vaxart Inc. has 3.8% of it’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Achieve Life Sciences Inc. -8.68% 61.33% 45.78% -23.66% -80.94% 100%
Vaxart Inc. -8.74% -18.54% -47.81% -45.6% -68.49% -11.17%

For the past year Achieve Life Sciences Inc. has 100% stronger performance while Vaxart Inc. has -11.17% weaker performance.

Summary

On 5 of the 9 factors Vaxart Inc. beats Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. It is developing Apatorsen to block the production of heat shock protein 27, a cell-survival protein expressed in various types of cancers, including bladder, prostate, breast, pancreatic, and non-small cell lung cancer. The company is headquartered in Bothell, Washington.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.